Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19-CAR-T cells (First Affiliated Hospital of Wenzhou Medical University)
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Wenzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is being developed by the First Affiliated Hospital of Wenzhou Medical University for the treatment of various refractory autoimmune diseases. The therapy utilizes genetically engineered T cells (either autologous or allogeneic) modified to express a CAR that specifically targets CD19, a surface marker found on B cells. By binding to CD19, the CAR-T cells induce the depletion of pathogenic B cells, aiming to 'reset' the immune system and achieve long-term remission in patients with conditions such as systemic lupus erythematosus, Sjogren's syndrome, and systemic sclerosis. It is currently being evaluated in an investigator-initiated early Phase 1 clinical trial.
- Other names
- Anti-CD19-CAR-T Cells InjectionAnti-CD-19-CAR-T Cells InjectionAnti-CD 19-CAR-T Cells Injection
02
Targets
Beyond the preview
Go deeper on anti-CD19-CAR-T cells (First Affiliated Hospital of Wenzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19-CAR-T cells (First Affiliated Hospital of Wenzhou Medical University).